Skip to content

US · UTMD · MEDICAL - INSTRUMENTS & SUPPLIES

Utah Medical Products, Inc. (UTMD) intrinsic value and stock valuation

$69.49as of 2026-11-21 · Mkt cap 226.73M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Utah Medical Products, Inc. DCF and intrinsic value

InvestorsCraft values UTMD with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from UTMD’s statements →

Utah Medical Products, Inc. Graham Number

Graham Number: $52.59d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Midvale, UT 84047-1048 utahmed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$38.5M-1.8% 5y CAGRd
20112025
Net income
$11.3M+0.9% 5y CAGRd
20112025
Free cash flow
$14.3M-5.8% 5y CAGRd
20112025
Total equity
$119.3M+3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$38.5M$40.9M$50.2M$52.3M$49.1M
Operating income$11.4M$13.6M$16.8M$19.8M$18.9M
Net income$11.3M$13.9M$16.6M$16.5M$14.8M
EPSd$3.48M$3.96M$4.57M$4.52M$4.04M
Operating cash flow$14.7M$14.8M$22.3M$21.2M$21.2M
Capital expenditure-$-370K-$-230K-$-640K-$-820K-$-550K
Free cash flow$14.3M$14.6M$21.6M$20.3M$20.7M
Total assets$122.5M$122.5M$135.5M$123.9M$115.6M
Total debt$230K$340K$290K$340K$400K
Net debt-$-85.53M-$-82.69M-$-92.57M-$-74.71M-$-60.58M
Total equity$119.3M$117.4M$128.3M$114.3M$107.1M
Cash and short-term investments$85.8M$83M$92.9M$75.1M$61M
Income statement
20252024202320222021
Revenue$38.5M$40.9M$50.2M$52.3M$49.1M
Cost of revenue$18.6M$16.8M$20.2M$20.1M$18.1M
Gross profit$19.9M$24.1M$30M$32.2M$30.9M
Research and development expenses$670K$810K$560K$490K$530K
Selling, general and administrative expenses$7.8M$5.57M$12.7M$11.9M$11.5M
Other expenses$0.00$4.17M$0.00$0.00$0.00
Operating expenses$8.47M$10.6M$13.3M$12.4M$12M
Cost and expenses$27.1M$27.3M$33.5M$32.5M$30.2M
Interest income$0.00$3.37M$0.00$660K$170K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.95M$2.77M$6.37M$7.08M$7.28M
Ebitda$17.1M$19.6M$24.8M$27.7M$26.3M
Operating income$11.4M$13.6M$16.8M$19.8M$18.9M
Total other income/expenses, net$2.71M$3.21M$3.31M$870K$180K
Income before tax$14.1M$16.8M$20.1M$20.7M$19.1M
Income tax expense$2.82M$2.93M$3.45M$4.19M$4.27M
Net income$11.3M$13.9M$16.6M$16.5M$14.8M
Weighted average shares outstanding$3.31M$3.5M$3.64M$3.64M$3.65M
Weighted average diluted shares outstanding$3.24M$3.5M$3.64M$3.64M$3.66M
Balance sheet
20252024202320222021
Cash and short-term investments$85.8M$83M$92.9M$75.1M$61M
Net receivables$3.52M$4.09M$3.39M$5.54M$5.13M
Inventory$7.93M$8.81M$9.58M$8.81M$6.6M
Total current assets$97.7M$96.3M$106.3M$89.9M$73.2M
Property, plant and equipment, net$9.91M$9.76M$10.6M$10.2M$10.6M
Goodwill and intangible assets$14.9M$16.5M$18.6M$23.7M$31.9M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$24.8M$26.2M$29.2M$34M$42.5M
Total assets$122.5M$122.5M$135.5M$123.9M$115.6M
Accounts payable$910K$540K$770K$1.22M$760K
Short-term debt$0.00$60K$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.6M$3.76M$4.71M$5.96M$3.75M
Long-term debt$230K$280K$290K$340K$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$680K$1.35M$2.44M$3.66M$4.75M
Capital lease obligations$230K$280K$290K$340K$400K
Total liabilities$3.27M$5.11M$7.14M$9.62M$8.5M
Common stock$30K$30K$40K$40K$40K
Retained earnings$128.7M$129.3M$138.3M$126M$115.3M
Accumulated other comprehensive income (loss)-$-9.42M-$-11.91M-$-10.66M-$-12.04M-$-9.05M
Total equity$119.3M$117.4M$128.3M$114.3M$107.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$230K$340K$290K$340K$400K
Net debt-$-85.53M-$-82.69M-$-92.57M-$-74.71M-$-60.58M
Cash flow statement
20252024202320222021
Net income$11.3M$13.9M$16.6M$16.5M$14.8M
Depreciation and amortization$3.01M$2.85M$6.37M$7.08M$7.28M
Stock-based compensation$370K$260K$230K$180K$170K
Change in working capital$320K-$-1.8M-$-230K-$-2.23M-$-1.01M
Accounts receivable$330K-$-780K$2.27M-$-530K-$-1.13M
Inventory$1.2M$590K-$-670K-$-2.35M-$-480K
Accounts payable$210K-$-70K-$-460K$460K-$-20K
Net cash provided by operating activities$14.7M$14.8M$22.3M$21.2M$21.2M
Investments in property, plant and equipment-$-370K-$-230K-$-640K-$-810K-$-550K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-370K-$-210K-$-640K-$-820K-$-550K
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-8.36M-$-19.97M$0.00-$-2.5M$0.00
Dividends paid-$-3.98M-$-4.26M-$-4.28M-$-3.16M-$-11.46M
Net cash used for financing activities-$-12.34M-$-23.84M-$-4.17M-$-5.48M-$-10.9M
Net change in cash$2.78M-$-9.89M$17.8M$14.1M$9.38M
Cash at end of period$85.8M$83M$92.9M$75.1M$61M
Operating cash flow$14.7M$14.8M$22.3M$21.2M$21.2M
Capital expenditure-$-370K-$-230K-$-640K-$-820K-$-550K
Free cash flow$14.3M$14.6M$21.6M$20.3M$20.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Utah Medical Products, Inc.

        Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.

        CEO
        Kevin L. Cornwell
        Employees
        155
        Beta
        0.36

        Explore

        Frequently asked questions

        What is the intrinsic value of Utah Medical Products, Inc. (UTMD)?

        Utah Medical Products, Inc. (UTMD) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is UTMD undervalued?

        UTMD trades at a price of $69.49 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.